Conference News

Daily IGRT Regimen for Prostate Cancer Improves Rectal Toxicity, Not OS

Daily IGRT Regimen for Prostate Cancer Improves Rectal Toxicity, Not OS

By

Researchers present findings of a comparison of daily image-guided radiotherapy (IGRT) vs a weekly regimen in patients with N0 localized prostate cancer at the 2018 GU Cancers Symposium.

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

By

Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence

Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence

By

Study results presented at the 2018 Gastrointestinal Cancers Symposium demonstrated the sensitivity and specificity of the CMx biomimetic platform, a novel approach to detecting CRC and precancerous lesions that could improve screening rates.

Better Postoperative Outcomes With RAMIE for Esophageal Cancer

Better Postoperative Outcomes With RAMIE for Esophageal Cancer

By

Research presented at the 2018 Gastrointestinal Cancers Symposium described benefits seen with RAMIE vs chemotherapy or chemoradiotherapy plus OTE for esophageal cancer.

SABCS: Modest Weight Loss Cuts Postmenopause Breast Cancer Risk

SABCS: Modest Weight Loss Cuts Postmenopause Breast Cancer Risk

Postmenopausal women with weight gain had increased risk of triple-negative breast cancer, research indicates.

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

High-Dose Dexamethasone Effective With Less Adverse Effects in ITP vs Corticosteroids

By

In this randomized trial, investigators sought to determine the effectiveness of high-dose dexamethasone vs conventional prednisone therapy in treatment-naïve patients with ITP. Results were presented at ASH 2017.

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

Aspirin Does Not Reduce Risk of Venous Thromboembolism in Multiple Myeloma

By

A retrospective study, presented at ASH 2017, determined the effectiveness of aspirin in reducing risk of VTE in patients with multiple myeloma at high risk of developing VTE.

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

Ruxolitinib Beneficial in Hydroxyurea Resistant/Intolerant Polycythemia Vera

By

Data presented at ASH 2017 confirm that ruxolitinib improves hematocrit control, hematologic remission, and reduction in spleen size in some patients with polycythemia vera who fail hydroxyurea.

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

Arterial Thrombotic Events Associated With First-line Nilotinib for CML in Older Adults

A retrospective analysis of patients with CML determined prevalence of arterial thrombotic events in those receiving nilotinib as first-line treatment and prevalence by patient age. Data were presented at ASH 2017.

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

By

Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.

Most Influential in Breast Reconstruction Decision: Surgeon, Spouse, GP

Most Influential in Breast Reconstruction Decision: Surgeon, Spouse, GP

By

A study from French researchers identified which people are the most likely to influence a breast cancer patient's decision whether to undergo breast reconstruction. These findings were presented at SABCS 2017.

MOCHA App Helps Breast Cancer Survivors Achieve Weight-Loss Goals

MOCHA App Helps Breast Cancer Survivors Achieve Weight-Loss Goals

By

A team from Methodist Hospital Cancer Center discuss an app developed at the facility that helps breast cancer survivors with nutrition and physical activity at SABCS 2017.

Physical Examination Sufficient Work-up for Complaints of Breast Pain

Physical Examination Sufficient Work-up for Complaints of Breast Pain

By

A single-center analysis demonstrates likelihood that mastalgia indicates presence of breast cancer and extensiveness of common work-up for the complaint. These findings were presented at SABCS 2017.

Bioimpedance Spectroscopy Reduces Chronic BCRL in High-Risk Breast Cancer

Bioimpedance Spectroscopy Reduces Chronic BCRL in High-Risk Breast Cancer

By

Results of a study evaluating the effectiveness of bioimpedance spectroscopy in reducing incidence of chronic breast cancer-related lymphedema (BCRL) in high-risk patients with breast cancer were presented at SABCS 2017.

EMBRACE at Dana-Farber Improves Care in Metastatic Breast Cancer

EMBRACE at Dana-Farber Improves Care in Metastatic Breast Cancer

By

A team from Dana-Farber Cancer Institute describe EMBRACE, their comprehensive care program for patients with metastatic breast cancer at SABCS 2017.

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer

Current Findings in Trial Evaluating Paclitaxel Substitution in Invasive Breast Cancer

By

Researchers presented an update of findings in the GeparSepto trial, which seeks to determine whether improvements in pathologic complete response can be translated to a survival benefit, at SABCS 2017.

Bio-individualized Diet Helps Breast Cancer Survivors Stabilize Weight, Glucose

Bio-individualized Diet Helps Breast Cancer Survivors Stabilize Weight, Glucose

By

Novel weight reduction plan helps breast cancer survivors achieve and maintain a healthy weight and glucose level, according to a presentation at SABCS 2017.

Best Antiemetic Therapies for Alleviating CINV: A Literature Review

Best Antiemetic Therapies for Alleviating CINV: A Literature Review

By

A review of 12 antiemetic regimens identified 3 that may be more effective than conventional regimens, a study presented at SABCS 2017 has shown.

Balancing Early Palliative Care With Active Treatment in Advanced Breast Cancer

Balancing Early Palliative Care With Active Treatment in Advanced Breast Cancer

By

An approach for incorporating palliative care into oncologic care early after diagnosis is explained in an education session at the 2017 SABCS.

Bisphosphonates vs Denosumab: Preventing SREs in Breast Cancer With Bone Metastasis

Bisphosphonates vs Denosumab: Preventing SREs in Breast Cancer With Bone Metastasis

By

A comparison study presented at the 2017 SABCS sought to determine the effectiveness of bisphosphonates with denosumab for skeletal-related events in women with breast cancer metastases to bone.

Adjuvant Therapy Duration a Continuous Discussion in HR+ Breast Cancer

Adjuvant Therapy Duration a Continuous Discussion in HR+ Breast Cancer

By

Choosing the optimal adjuvant therapy option for a patient with early-stage HR-positive breast cancer should be a continuous discussion with the patient, according to a presentation at SABCS 2017.

Epigenetic Modulation, Checkpoint Inhibition Showed Potential in HER2 Breast Cancer

Epigenetic Modulation, Checkpoint Inhibition Showed Potential in HER2 Breast Cancer

By

Using a mouse model of HER2+ breast cancer, researchers tested the efficiency of combined epigenetic modulation and checkpoint inhibition using the histone deacetylase inhibitor ENT and antibodies for 2 checkpoint inhibitor proteins. These findings were presented at the 2017 SABCS.

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

Adjuvant Endocrine Therapy Benefits Younger Women With ER+ Breast Cancer

By

A comparison of adjuvant endocrine therapies showed one option provided greater reduction in disease recurrence among premenopausal women with ER+ breast cancer.

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

By

Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

Ibrutinib Effective As First-line Therapy in Waldenström's Macroglobulinemia

By

Ibrutinib — a Bruton tyrosine kinase inhibitor — is currently used among patients with WM who have previously received treatment. This prospective, phase 2 study sought to determine its efficacy as a first-line therapy in treatment-naive patients.

Oncotype DX Recurrence Score a Potential Marker of Hereditary Breast Cancer

Oncotype DX Recurrence Score a Potential Marker of Hereditary Breast Cancer

By

Researchers conducted a review of more than 400 patients with hormone receptor-positive breast cancer to determine if high Oncotype DX RS is associated with a greater likelihood the cancer is hereditary.

Markers Identified for Cardiotoxicity Due to Chemotherapy for Breast Cancer

Markers Identified for Cardiotoxicity Due to Chemotherapy for Breast Cancer

By

Biomarker analysis revealed markers for cardiotoxicity enabling early initiation of heart failure therapy in patients with breast cancer who were treated with chemotherapy.

Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions

Refined Equation May Obviate Oncotype DX in Breast Cancer Treatment Decisions

By

Research presented at SABCS 2017 demonstrated the effect of refining the linear predictor for determining which patients with breast cancer would potentially benefit from adjuvant chemotherapy.

Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis

Risk Factors for Brain Metastases in HER2+ Breast Cancer Identified in Analysis

By

A retrospective analysis presented at 2017 SABCS reveals the factors that indicate a higher risk of developing brain metastases for women with HER2+ breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs